Biomapas Insights: Selecting the Right CRO at the right time – What Biotechs Need to Know

Choosing a CRO directly influences speed, feasibility, regulatory clarity, and study quality. Hence, for emerging biotechs planning early-phase and first-in-human studies, the right timing and partnership can prevent delays, strengthen operational efficiency, and improve decision-making from the very start.

During the discussion, we explore:

• The most common mistakes biotechs make when planning their first trial
• When sponsors should start thinking about their CRO partner
• What matters most when evaluating a CRO for early-phase studies
• How do smaller CROs compare to global providers in early oncology development
• How early regulatory or scientific advice can change the trajectory of a study

Whether you are preparing for your first-in-human study or scaling early-phase oncology programs, this conversation offers grounded, experience-driven guidance.